Elicera Therapeutics AB (ELIC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Elicera Therapeutics AB (ELIC) has a cash flow conversion efficiency ratio of -0.156x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-4.74 Million ≈ $-509.90K USD) by net assets (Skr30.33 Million ≈ $3.26 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Elicera Therapeutics AB (ELIC) defensive interval to measure how many days the company can operate on defensive assets alone.
Elicera Therapeutics AB - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Elicera Therapeutics AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Elicera Therapeutics AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Elicera Therapeutics AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Inter-M Corporation
KQ:017250
|
0.026x |
|
In8bio Inc
NASDAQ:INAB
|
-0.217x |
|
Weizmann Limited
NSE:WEIZMANIND
|
0.281x |
|
Korea Mcnulty Co Ltd
KQ:222980
|
0.053x |
|
Vitura Health Ltd
AU:VIT
|
-0.030x |
|
Southern Hemisphere Mining Ltd
AU:SUH
|
-1.457x |
|
Asuransi Jiwa Syariah Jasa Mitra Abadi Tbk PT
JK:JMAS
|
-0.165x |
|
Jadi Imaging Holdings Bhd
KLSE:7223
|
0.001x |
Annual Cash Flow Conversion Efficiency for Elicera Therapeutics AB (2017–2024)
The table below shows the annual cash flow conversion efficiency of Elicera Therapeutics AB from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Elicera Therapeutics AB worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr20.77 Million ≈ $2.24 Million |
Skr-23.46 Million ≈ $-2.53 Million |
-1.130x | -24.16% |
| 2023-12-31 | Skr16.40 Million ≈ $1.77 Million |
Skr-14.92 Million ≈ $-1.61 Million |
-0.910x | -248.18% |
| 2022-12-31 | Skr32.80 Million ≈ $3.53 Million |
Skr-8.57 Million ≈ $-922.36K |
-0.261x | +4.50% |
| 2021-12-31 | Skr52.24 Million ≈ $5.62 Million |
Skr-14.29 Million ≈ $-1.54 Million |
-0.274x | -209.39% |
| 2020-12-31 | Skr10.24 Million ≈ $1.10 Million |
Skr-905.25K ≈ $-97.42K |
-0.088x | +77.29% |
| 2019-12-31 | Skr614.10K ≈ $66.09K |
Skr-239.16K ≈ $-25.74K |
-0.389x | -31.11% |
| 2018-12-31 | Skr805.16K ≈ $86.65K |
Skr-239.16K ≈ $-25.74K |
-0.297x | -0.44% |
| 2017-12-31 | Skr808.69K ≈ $87.03K |
Skr-239.16K ≈ $-25.74K |
-0.296x | -- |
About Elicera Therapeutics AB
Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing EL… Read more